Grail Stock Surges Over 50% After FDA Committee Votes in Favor of Galleri MCED Test
Grail (NASDAQ: GRAL) stock surged over 55% following a favorable vote from an FDA advisory committee on its multi-cancer early detection test, Galleri. The Molecular and Clinical Genetics Devices Panel voted unanimously for the safety of the test, with seven to two in favor of benefits outweighing risks, and six to four on effectiveness. This outcome increases the likelihood of pre-market approval by the FDA, potentially leading to broader adoption among medical professionals and insurers. Despite missing its primary endpoint—showing a statistically significant reduction in late-stage cancer detection—the test demonstrated strong episode sensitivity for 12 deadly cancers responsible for two-thirds of cancer deaths. Grail's management argues that early detection could lead to cost savings from treating less advanced stages, which may encourage insurer adoption if the benefits outweigh testing costs and false positives. The FDA vote is a significant milestone for Grail as it moves closer to regulatory approval and commercialization.
Tickers: $GRAL